» Articles » PMID: 24792911

Downmodulation of Tumor Suppressor P53 by T Cell Receptor Signaling is Critical for Antigen-specific CD4(+) T Cell Responses

Overview
Journal Immunity
Publisher Cell Press
Date 2014 May 6
PMID 24792911
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Antigen specificity is critical in immune response and requires integration of antigen-specific signals with antigen-nonspecific signals such as those provided by cytokines. The mechanism integrating these pathways is incompletely understood. We report here that antigen-specific proliferative responses of CD4(+) T cells required downmodulation of tumor suppressor p53. In the absence of T cell receptor (TCR) signal, IL-2 induced sustained increase in p53 protein, which prevented proliferative responses despite strong signaling through the IL-2 receptor. In contrast, TCR signaling resulted in early termination of p53 protein expression by decreasing p53 mRNA as well as strong transcriptional induction of the p53-regulating protein Mdm2. Downmodulation of p53 in response to antigen stimulation was in fact critical for antigen-specific T cell proliferation, and preventing p53 degradation by inhibiting Mdm2 resulted in sustained p53 protein and prevented antigen-specific T cell proliferation. It is thus termination of p53 by TCR signaling that allows proliferative responses, enforcing antigen specificity.

Citing Articles

Modulation of TCR stimulation and pifithrin-α improve the genomic safety profile of CRISPR-engineered human T cells.

Ursch L, Muschen J, Ritter J, Klermund J, Bernard B, Kolb S Cell Rep Med. 2024; 5(12):101846.

PMID: 39637860 PMC: 11722128. DOI: 10.1016/j.xcrm.2024.101846.


MDM2 inhibitors in cancer immunotherapy: Current status and perspective.

Zeng Q, Zeng S, Dai X, Ding Y, Huang C, Ruan R Genes Dis. 2024; 11(6):101279.

PMID: 39263534 PMC: 11388719. DOI: 10.1016/j.gendis.2024.101279.


ISG15/GRAIL1/CD3 axis influences survival of patients with esophageal adenocarcinoma.

McEwen D, Ray P, Nancarrow D, Wang Z, Kasturirangan S, Abdullah S JCI Insight. 2024; 9(13).

PMID: 38781019 PMC: 11383178. DOI: 10.1172/jci.insight.179315.


Understanding the complexity of p53 in a new era of tumor suppression.

Liu Y, Su Z, Tavana O, Gu W Cancer Cell. 2024; 42(6):946-967.

PMID: 38729160 PMC: 11190820. DOI: 10.1016/j.ccell.2024.04.009.


DNA framework signal amplification platform-based high-throughput systemic immune monitoring.

Chen Y, Chen X, Zhang B, Zhang Y, Li S, Liu Z Signal Transduct Target Ther. 2024; 9(1):28.

PMID: 38320992 PMC: 10847453. DOI: 10.1038/s41392-024-01736-0.


References
1.
McHeyzer-Williams L, McHeyzer-Williams M . Antigen-specific memory B cell development. Annu Rev Immunol. 2005; 23:487-513. DOI: 10.1146/annurev.immunol.23.021704.115732. View

2.
Harty J, Badovinac V . Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol. 2008; 8(2):107-19. DOI: 10.1038/nri2251. View

3.
Chen D, Shan J, Zhu W, Qin J, Gu W . Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature. 2010; 464(7288):624-7. PMC: 3737736. DOI: 10.1038/nature08820. View

4.
Phan R, Dalla-Favera R . The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004; 432(7017):635-9. DOI: 10.1038/nature03147. View

5.
Smith-Garvin J, Koretzky G, Jordan M . T cell activation. Annu Rev Immunol. 2009; 27:591-619. PMC: 2740335. DOI: 10.1146/annurev.immunol.021908.132706. View